#### **Supplementary Material**

# Non-steroidal anti-inflammatories for analgesia in critically ill patients: a systematic review and meta-analysis of randomized control trials

Chen-Hsiang Ma, BSc<sup>1</sup>

Kimberly B. Tworek, BScN<sup>1</sup>

Janice Y. Kung, MLIS<sup>2</sup>

Sebastian Kilcommons, BSc<sup>1</sup>

Kathleen Wheeler, MD<sup>3</sup>

Arabesque Parker, MD, MSc<sup>4</sup>

Janek Senaratne, MD, MSc<sup>4</sup>

Erika Macintyre, MD<sup>4</sup>

Wendy Sligl, MD, MSc<sup>4</sup>

Constantine J. Karvellas, MD, MSc<sup>4</sup>

Fernando G Zampieri, MD, PhD<sup>4</sup>

Demetrios Jim Kutsogiannis, MD, MSc<sup>4</sup>

John Basmaji, MD<sup>5</sup>

Kimberley Lewis, MD, MSc<sup>6,7</sup>

Dipayan Chaudhuri, MD, MSc<sup>6,7</sup>

Sameer Sharif, MD<sup>7</sup>

Oleksa G. Rewa, MD, MSc<sup>4,8</sup>

Bram Rochwerg, MD, MSc<sup>6,7</sup>

Sean M. Bagshaw, MD, MSc<sup>4,8,9</sup>

Vincent I. Lau, MD, MSc<sup>4</sup>

- 1. Faculty of Medicine and Dentistry, University of Alberta, and Alberta Health Services, Edmonton, Alberta, Canada.
- 2. John W. Scott Health Sciences Library, University of Alberta, Edmonton, Alberta, Canada.
- 3. Department of Anesthesia, McMaster University, Hamilton, Ontario, Canada.
- 4. Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta, and Alberta Health Services, Edmonton, Alberta, Canada.
- 5. Department of Medicine, Division of Critical Care, Western University, London, Ontario, Canada.
- Department of Health Research Methods, Evidence & Impact, McMaster University, Hamilton, Ontario, Canada.
- Department of Medicine, Division of Critical Care, McMaster University, Hamilton, Ontario, Canada.
- 8. School of Public Health, University of Alberta, Edmonton, Alberta, Canada.
- 9. Critical Care Strategic Clinical Network, Alberta Health Services, Edmonton, Alberta, Canada

<u>Corresponding Author</u>: Vincent Lau\*, Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta and Alberta Health Services, 8440 112 Street, Edmonton, Alberta, Canada; vince.lau@ualberta.ca

Section and Topic	ltem #	Checklist item	Location where item is reported			
TITLE						
Title	1	Identify the report as a systematic review.	1-3			
ABSTRACT	-					
Abstract	2	See the PRISMA 2020 for Abstracts checklist.				
INTRODUCTION	-					
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	6, 7			
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	7			
METHODS	-					
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	8			
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	7			
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	7			
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	7, 8			
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	8, 9			
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	8			
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	8, 9			
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	9			
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	9, 10			
Synthesis methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).	8			
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	9			
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	9, 10			
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	9			
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).	10			
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	10			
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	9			
Certainty assessment	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	9			
RESULTS	<u> </u>					
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	12			
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	8			
Study characteristics	17	Cite each included study and present its characteristics.	10, 11, 13			

### Supplementary Table 1 Preferred Reporting Items for Systematic reviews and Meta-Analyses guideline checklist (DEFERRED UNTIL EDITS ARE COMPLETE!)

Section and Topic	ltem #	Checklist item	Location where item is reported					
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	13					
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.						
Results of	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	10, 11, 14					
syntheses	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.						
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	14					
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	N/A					
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	14					
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	15					
DISCUSSION								
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	18					
	23b	Discuss any limitations of the evidence included in the review.	20, 21					
	23c	Discuss any limitations of the review processes used.	20, 21					
	23d	Discuss implications of the results for practice, policy, and future research.	20, 21					
OTHER INFORMATIO	N							
Registration and	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	7					
protocol	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	7					
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	N/A					
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	2					
Competing interests	26	Declare any competing interests of review authors.	2					
Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	Within supplementary document.					

# Supplementary Table 2 Database search strategy

Database	Search Strategy								
MEDLINE	<ol> <li>exp Anti-Inflammatory Agents, Non-Steroidal/</li> <li>NSAID* mp</li> </ol>								
Ovid MEDLINE(R) ALL 1946 to May 27, 2022	<ol> <li>NSAD .mp.</li> <li>(nonsteroidal anti-inflammator* or nonsteroidal antiinflammator*).mp.</li> <li>(non-steroidal anti-inflammator* or non-steroidal antiinflammator*).mp.</li> <li>(celecoxib* or etoricoxib* or lumiracoxib*).mp.</li> <li>diclofenac*.mp.</li> <li>etodolac.mp.</li> <li>(fenoprofen* or flurbiprofen*).mp.</li> </ol>								
	9. aspirin.mp.								
	11. indomethacin*.mp.								
	<ol> <li>(ketoprofen* or ketorolac* or piroxicam* or bromfenac* or oxyphenbutazone* or suprofen*).mp.</li> </ol>								
	13. mefenamic acid.mp.								
	14. meloxicam.mp. 15. naproxen*.mp.								
	16. sulindac.mp.								
	17. tolmetin.mp.								
	18. or/1-17								
	19. Analgesia/ 20. analge* mp								
	21. (pain adj3 (manag* or control* or reduc* or alleviat* or mitigat*)).mp.								
	22. (pain*1 adj3 (medicat* or relief*)).tw,kf.								
	23. (pain adj2 (score* or intensit* or scale*)).tw,kf.								
	24. ((visual* analog* adj3 (scale* or score*)) and pain).tw,kf.								
	25. exp Pain Management/ 26. Pain/dt or Pain/pc or Pain. Postoperative/dt or Pain Measurement/								
	27. or/19-26								
	28. Emergency Treatment/ or Emergency Medicine/ or Emergency Medical Services/ or Emergency Service, Hospital/ or Trauma Centers/ or Triage/ or exp Evidence-Based Emergency Medicine/ or exp Emergency Nursing/ or Emergencies/ or exp Intensive Care Units/ or Critical Care/ or Critical Illness/ or emergicent*.mp. or casualty department*.mp. or ((emergenc* or ED) adj1 (room* or accident or ward or wards or unit or units or department* or physician* or doctor* or nurs* or treatment* or visit*)).mp. or (triage or critical care or critical* ill* or (trauma adj1 (cent* or care))).mp.								
	29. (intensive care or ICU).mp.								
	<ol> <li>30. (Intensive therapy unit* or high dependency unit* or coronary care unit* or mechanical ventilat* or noninvasive ventilat*).mp.</li> <li>21. or /28.20</li> </ol>								
	31. 07/28-30 32 18 and 27 and 31								
	33. randomized controlled trial.pt.								
	34. clinical trial.pt.								
	<ul><li>35. randomi?ed.ti,ab.</li><li>36. placebo.ti,ab.</li></ul>								

	<ul> <li>37. dt.fs.</li> <li>38. randomly.ti,ab.</li> <li>39. trial.ti,ab.</li> <li>40. groups.ti,ab.</li> <li>41. or/33-40</li> <li>42. animals/</li> <li>43. humans/</li> <li>44. 42 not (42 and 43)</li> <li>45. 41 not 44</li> <li>46. 32 and 45</li> </ul>
Embase Ovid Embase 1974 to 2022 May 27	<ol> <li>exp nonsteroid antiinflammatory agent/</li> <li>NSAID*.mp.</li> <li>(non-steroidal anti-inflammator* or nonsteroidal antiinflammator*).mp.</li> <li>(non-steroidal anti-inflammator* or non-steroidal antiinflammator*).mp.</li> <li>(celecoxib* or etoricoxib* or lumiracoxib*).mp.</li> <li>diclofenac*.mp.</li> <li>etodolac.mp.</li> <li>(fenoprofen* or flurbiprofen*).mp.</li> <li>aspirin.mp.</li> <li>indomethacin*.mp.</li> <li>(ketoprofen* or ketorolac* or piroxicam* or bromfenac* or oxyphenbutazone* or suprofen*).mp.</li> <li>mefenamic acid.mp.</li> <li>(ketoprofen* or ketorolac* or piroxicam* or bromfenac* or oxyphenbutazone* or suprofen*).mp.</li> <li>mefenamic acid.mp.</li> <li>meloxicam.mp.</li> <li>naproxen*.mp.</li> <li>olmetin.mp.</li> <li>ordinac.mp.</li> <li>ordinac.mp.</li> <li>ordinac.mp.</li> <li>ordinac.mp.</li> <li>ordinac.mp.</li> <li>ordinac.mp.</li> <li>sulindac.mp.</li> <li>ordinac.mp.</li> <li>(pain adj3 (mang* or control* or reduc* or alleviat* or mitigat*)).mp.</li> <li>(pain adj3 (medicat* or relief*)).tw,kw.</li> <li>(pain adj2 (score* or intensit* or scale*)).tw,kw.</li> <li>(visual* analog* adj3 (scale* or score*)) and pain).tw,kw.</li> <li>or/19-25</li> <li>emergency treatment/ or emergency medicine/ or emergency health service/ or hospital emergency service/ or exp evidence based emergency medicine/ or exp emergency nursing/ or emergency ro casulty department*.mp. or (temergenc* or or ED) adj1 (room* or accident or ward or wards or unit or units or department* or physician* or doctor* or nurs* or treatment* or visit*)).mp. or (triage or critical care or critical illness/ or emergency treatment* or sories)).mp.</li> <li>(intensive care or ICU).mp.</li> <li>(intensive tare or ICU).mp.</li> </ol>

	<ol> <li>or/27-29</li> <li>18 and 26 and 30</li> <li>Randomized controlled trial/ or Controlled clinical study/ or randomization/ or intermethod comparison/ or double blind procedure/ or human experiment/</li> <li>(random\$ or placebo or (open adj label) or ((double or single or doubly or singly) adj (blind or blinded or blindly)) or parallel group\$1 or crossover or cross over or ((assign\$ or match or matched or allocation) adj5 (alternate or group\$1 or intervention\$1 or patient\$1 or subject\$1 or participant\$1)) or assigned or allocated or (controlled adj7 (study or design or trial)) or volunteer or volunteers).ti,ab.</li> <li>(compare or compared or comparison or trial).ti.</li> <li>((evaluated or evaluate or evaluating or assessed or assess) and (compare or compared or comparing or comparison).ab.</li> <li>or/32-35</li> <li>(random\$ adj sampl\$ adj7 (cross section\$ or questionnaire\$1 or survey\$ or database\$11).ti,ab. not (comparative study/ or controlled study/ or randomi?ed controlled.ti,ab. or randomly assigned.ti,ab.)</li> <li>Cross-sectional study/ not (randomized controlled trial/ or controlled clinical study/ or controlled study/ or randomi?ed controlled trial/ or controlled clinical study/ or controlled study/ or randomi?ed controlled trial.</li> <li>((case adj control\$) and random\$) not randomi?ed controlled.ti,ab.</li> <li>((systematic review not (trial or study)).ti.</li> <li>(nonrandom\$ not random\$, ti,ab.</li> <li>(review.ab. and review.pt.) not trial.ti.</li> <li>"we searched".ab. and (review.ti. or review.pt.)</li> <li>update review.ab.</li> <li>(rat or rats or mouse or mice or swine or porcine or murine or sheep or lambs or pigs or piglets or rabbit or rabbits or cat or cats or dog or dogs or cattle or bovine or monkey or monkeys or trout or marmoset\$1.1.ti. and animal experiment/</li> <li>Animal experiment/ not (human experiment/ or human/)</li> <li>or/37-49</li> <li>36 not 50</li> <li>31 and 51</li> </ol>
CINAHL	<ul> <li>S1 (MH "Antiinflammatory Agents, Non-Steroidal+")</li> <li>S2 NSAID*</li> <li>S3 nonsteroidal anti-inflammator* or nonsteroidal antiinflammator*</li> <li>S4 non-steroidal anti-inflammator* or non-steroidal antiinflammator*</li> <li>S5 celecoxib* or etoricoxib* or lumiracoxib*</li> <li>S6 diclofenac*</li> <li>S7 etodolac</li> <li>S8 fenoprofen* or flurbiprofen*</li> <li>S9 aspirin</li> <li>S10 ibuprofen*</li> <li>S11 indomethacin*</li> <li>S12 ketoprofen* or ketorolac* or piroxicam* or bromfenac* or oxyphenbutazone* or suprofen*</li> </ul>

	<ul> <li>S13 mefenamic acid</li> <li>S14 meloxicam</li> <li>S15 naproxen*</li> <li>S16 sulindac</li> <li>S17 tolmetin</li> </ul>
	<ul> <li>S18 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17</li> <li>S19 (MH "Analgesia+")</li> <li>S20 analge*</li> </ul>
	S21 (pain N3 (manag* or control* or reduc* or alleviat* or mitigat*)) S22 (pain* N3 (medicat* or relief*)) S23 (pain N2 (score* or intensit* or scale*)) S24 ((intensit* or intensit* or scale*))
	S24 ((Visual* analog* N3 (scale* or score*)) and pain) S25 (MH "Pain Management") S26 (MH "Pain+/DT/PC") S27 (MH "Postoperative Pain")
	<ul> <li>S28 (MH "Pain Measurement")</li> <li>S29 S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28</li> <li>S30 (MH "Emergency Service+") or (MH "Emergency Medicine") or (MH "Physicians, Emergency") OR (MH "Emergency Nurse Practitioners") or (MH "Emergency Nursing+") or (MH "Emergency Patients") or "casualty department*" or ((emergenc* or "ED") N1 (room* or accident or ward or wards or unit or units or department* or physician* or doctor* or nurs* or treatment* or visit*)) or (triage or (trauma N1 (cent* or care)))</li> </ul>
	S31 (MH "Intensive Care Units+") S32 (MH "Critical Care+") S33 (MH "Critical Illness")
	<ul> <li>S34 Intensive care of Color critical care of critical and</li> <li>S35 intensive therapy unit* or high dependency unit* or coronary care unit* or</li> <li>mechanical ventilat* or noninvasive ventilat*</li> <li>S36 S30 OR S31 OR S32 OR S33 OR S34 OR S35</li> <li>S37 S18 AND S26</li> </ul>
	<ul> <li>S37 S18 AND S29 AND S36</li> <li>S38 (MH (randomized controlled trials OR double-blind studies OR single-blind studies OR random assignment OR pretest-posttest design OR cluster sample ) OR TI (randomised OR randomized ) OR AB random* OR TI trial OR ((MH (sample size) AND AB (assigned OR allocated OR control))) OR MH (placebos OR crossover design OR comparative studies ) OR AB (control W5 group) OR (cluster W3 RCT) OR PT (randomized controlled trial)) ) NOT ((MH animals+ OR MH (animal studies) OR TI (animal model*)) NOT MH (human))</li> <li>S39 S37 AND S38</li> </ul>
Cochrane Library	<ul> <li>#1 [mh "Anti-Inflammatory Agents, Non-Steroidal"]</li> <li>#2 NSAID*</li> <li>#3 nonsteroidal anti-inflammator* or nonsteroidal antiinflammator*</li> <li>#4 non storoidal anti-inflammator* or non-storoidal antiinflammator*</li> </ul>
	<ul> <li>#4 non-steroidal anti-inflatinator or non-steroidal antilmammator</li> <li>#5 celecoxib* or etoricoxib* or lumiracoxib*</li> <li>#6 diclofenac*</li> <li>#7 etodolac</li> </ul>

<ul> <li>#32 [mh "Critical Care"]</li> <li>#33 [mh "Critical Illness"]</li> <li>#34 critical care or critical* NEXT ill*</li> <li>#35 intensive care or ICU</li> <li>#36 intensive therapy unit* or high dependency unit* or coronary care unit* or mechanical ventilat* or noninvasive ventilat*</li> <li>#27 {OP #20 #26}</li> </ul>
<ul> <li>#30 [Init' enlergency treatment'] of [Init' enlergency medicine'] of [Init's enlergency health service"] or [mh "ewidence based emergency medicine"] or [mh "emergency nursing"] or [mh ^"emergency care"] or [mh "emergency ward"] or [mh "emergency"] or (triage or casualty department* or "A&amp;E" or "A and E"):ti,ab,kw or ((emergenc* or ED) near (room* or accident or ward or wards or unit or units or department* or physician* or doctor* or nurs* or treatment* or presentation or patient* or visit*)):ti,ab,kw</li> <li>#31 [mh "Intensive Care Units"]</li> </ul>
<pre>#28 [mh "Pain Measurement"] #29 {OR #19-#28} #20 [wh "for the form of the</pre>
<ul> <li>#20 Intestricted and the cost and with qualifier(s): [and generaty 21, prevention &amp; control - PC]</li> <li>#27 MeSH descriptor: [Pain, Postoperative] explode all trees and with qualifier(s): [drug therapy DT]</li> </ul>
<ul> <li>#24 ((Visual analog 'NEAR/3 (scale or score ')) and pain)</li> <li>#25 [mh "Pain Management"]</li> <li>#26 MeSH descriptor: [Pain] explode all trees and with qualifier(s): [drug therapy - DT</li> </ul>
<ul> <li>#22 (pain* NEAR/3 (medicat* or relief*))</li> <li>#23 (pain NEAR/2 (score* or intensit* or scale*))</li> <li>#24 (viewel* enclose* NEAR/2 (coole* or scale*))</li> </ul>
<ul> <li>#20 analge*</li> <li>#21 (pain NEAR/3 (manag* or control* or reduc* or alleviat* or mitigat*))</li> </ul>
#17 tolmetin #18 {OR #1-#17} #19 [mh Analgesia]
<pre>#14 metokeum #15 naproxen* #16 sulindac</pre>
#13 mefenamic acid #14 meloxicam
<ul> <li>#10 ibuprofen*</li> <li>#11 indomethacin*</li> <li>#12 ketoprofen* or ketorolac* or piroxicam* or bromfenac* or oxyphenbutazone* or</li> </ul>
<ul><li>#8 fenoprofen* or flurbiprofen*</li><li>#9 aspirin</li></ul>

# Supplemental Table 3 Risk of bias assessment for randomized control studies

<u>Studies</u> :	Adequate sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants/study personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data addressed (attrition bias)	Free from selective reporting (reporting bias)	Free from other bias	Overall risk of bias
Arslan 2018	LR	LR	LR	LR	LR	LR	LR	LR
Aubrun 2000	LR	LR	LR	LR	LR	LR	LR	LR
Bameshki 2015	LR	LR	LR	LR	LR	LR	LR	LR
Barilaro 2001	PHR	PHR	PHR	LR	LR	LR	LR	PHR
Fayaz 2004	LR	LR	LR	LR	HR	LR	LR	HR
Hynninen 2000	LR	LR	LR	LR	LR	LR	LR	LR
Imantalab 2014	LR	LR	PHR	LR	LR	LR	LR	PHR
Osojnik 2020	PLR	LR	LR	LR	LR	LR	LR	PLR
Khalil 2006	PHR	LR	LR	LR	LR	LR	LR	PHR
Koizuka 2004	LR	LR	LR	LR	LR	PHR	LR	PHR
Maddali 2006	LR	LR	HR	LR	LR	LR	LR	HR
Oberhofer 2005	PHR	PHR	LR	LR	LR	LR	LR	PHR
Ott 2003	PLR	PLR	LR	HR	LR	LR	LR	HR
Rapanos 1999	LR	LR	LR	LR	LR	LR	LR	LR
Vassen 2012	IR	LR	LR	LR	LR	LR	LR	LR

Low risk	LR
Probably low risk	PLR
Probably high risk	PHR
High risk	HR
Unclear	N/A

Supplemental Fig. 1 Subgroup analyses of low risk versus high risk of bias studies in A opioid consumption in oral morphine equivalents, B pain scores in visual analogue scale, C duration of mechanical ventilation, D intensive care unit length of stay, and E bleeding

Study or Subgroup	NSAID Adjuvant Mean SD Tota as studies	No Adjuvant I Mean SD Total Wei	Mean Difference ght IV, Random, 95% Cl	Mean Difference IV, Random, 95% Cl
Fayaz 2004 Oberhofer 2005 <b>Subtotal (95% CI)</b> Heterogeneity: Tau <sup>2</sup> = Test for overall effect	$81   36   17 \\ 38.6   6.2   27 \\ 38 \\ = 142.17;   Chi2 = 2.56 \\ :   Z = 1.52   (P = 0.13) \\ \end{cases}$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	<ul> <li>.7% -30.00 [-56.11, -3.89]</li> <li>.7% -8.40 [-12.67, -4.13]</li> <li>.4% -15.20 [-34.86, 4.46]</li> </ul>	
1.1.2 Low risk of bia Aubrun 2000 Bameshki 2015 Hynninen 2000 Hynninen 2000 Raspanos 1999 Yassen 2012 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect	s studies 99 60 2: 42.9 11.7 3: 63 41.7 2: 81 42.6 2: 67.2 37.7 3: 63.7 12.3 2: 60.78; Chi <sup>2</sup> 12.9 = 60.78; Chi <sup>2</sup> 12.9 : 2 = 5.24 (P < 0.000	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	5%         -48.00 [-82.10, -13.900]           6%         -21.30 [-30.57, -12.03]           1.1%         -16.50 [-36.61, 3.61]           1.8%         -1.9           9%         -2.52 (-43.61, -6.79)           9%         -4.00 [-73.42, -8.18]           5%         -30.00 [-37.37, -22.63]           1.6%         -23.46 [-32.24, -14.68]	
<b>Total (95% CI)</b> Heterogeneity: Tau <sup>2</sup> = Test for overall effect Test for subgroup diff	<b>236</b> = 130.27; Chi <sup>2</sup> = 37.8 : Z = 4.38 (P < 0.000 ferences: Chi <sup>2</sup> = 0.56	$\begin{array}{c} 5 & 244 & 100\\ 81, df = 8 \ (P < 0.00001); \ l^2 \\ 11)\\ 5, df = 1 \ (P = 0.45), \ l^2 = 0\% \end{array}$	<b>.0% -21.38 [-30.95, -11.81]</b> = 79%	-100 -50 0 50 100 Favours NSAIDs Favours no NSAIDs
B Study or Subgroup	NSAID Adjuvant	No Adjuvant al Mean SD Total Wei	Mean Difference	Mean Difference
1.2.1 High risk of bi Raspanos 1999 Yassen 2012 Subtotal (95% Cl) Heterogeneity: Tau <sup>2</sup> - Test for overall effect	Interaction         SD         Form           ias studies         24         24         33           27         8         26         66           =         0.00; Chi <sup>2</sup> = 0.10,         10,         10,           t:         Z         6,07         (P < 0.00)	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	-9.00 [-20.68, 2.68] .0% -11.00 [-14.66, -7.34] .7% -10.82 [-14.32, -7.33]	
1.2.2 Low risk of bia Aubrun 2000 Imantalab 2014 Koizuka 2004 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> Test for overall effect	as studies 51 6 2 24.3 8.5 6 22 6.5 1 9 = 49.64; Chi <sup>2</sup> = 28.4 t: Z = 0.90 (P = 0.37	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	.0% -12.00 [-15.61, -8.39] .4% -0.20 [-3.37, 2.97] .8% 1.00 [-3.81, 5.81] .3% -3.79 [-12.08, 4.49] = 93%	
Total (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect Test for subgroup dif	15 = 40.66; Chi <sup>2</sup> = 39.0 t: Z = 1.94 (P = 0.05 fferences: Chi <sup>2</sup> = 2.3	<b>8 152 100</b> 00, df = 4 (P < 0.00001); $ ^2$ ) 5, df = 1 (P = 0.13), $ ^2$ = 57	-6.05 [-12.15, 0.06] = 90%	-20 -10 0 10 20 Favours NSAIDs Favours no NSAIDs
C Study or Subgroup	NSAID Adjuvant Mean SD Tot	No Adjuvant al Mean SD Total Wo	Mean Difference eight IV, Random, 95% CI	Mean Difference IV, Random, 95% Cl
1.3.1 High risk of bi Barilaro 2001 Fayaz 2004 Khalil 2006 Koizuka 2004 Maddal 2006 Osojnik 2020 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> Test for overal effect	ias studies           13.6         3           10         5           0.79         0.5           3.48         1.4           7.18         3.8           9         5           11         1.17; Chi <sup>2</sup> = 15.2*           t: Z = 2.54 (P = 0.01)         1.17; Chi <sup>2</sup> = 15.2*	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	9.5% -3.00 [-5.53, -0.47] 7.3% -2.00 [-5.23, 1.23] 6.9% -0.74 [-1.32, -0.16] 5.0% 0.03 [-1.13, 1.19] 2.4% -3.70 [-5.49, -1.91] 9.5% -1.100 [-3.54, 1.54] 9.5% -1.49 [-2.64, -0.34] 7%	
<b>1.3.2 Low risk of bia</b> Arslan 2018 Raspanos 1999 <b>Subtotal (95% CI)</b> Heterogeneity: Tau <sup>2</sup> Test for overall effect	as studies 7.53 1.77 7.17 3.1 = 4.42; Chi <sup>2</sup> = 10.83 t: Z = 0.95 (P = 0.34	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	6.9% -2.92 [-3.51, -2.33] 2.5% 0.20 [-1.56, 1.96] 9.4% -1.48 [-4.52, 1.57] 91%	-
<b>Total (95% CI)</b> Heterogeneity: Tau <sup>2</sup> Test for overall effect Test for subgroup dil	24 = 1.92; Chi <sup>2</sup> = 46.1: t: Z = 2.70 (P = 0.00 fferences: Chi <sup>2</sup> = 0.0	$\begin{array}{cccc} 40 & 240 & 10\\ 8,  df = 7 \; (P < 0.00001); \; l^2 = \\ 77 \\ 00,  df = 1 \; (P = 0.99), \; l^2 = 0 \end{array}$	0.0% -1.57 [-2.72, -0.43] = 85% %	-10 -5 0 5 10 Favours NSAIDs Favours no NSAIDs
	NSAID Adjuvant Mean SD Tol	No Adjuvant al Mean SD Total We	Mean Difference	Mean Difference
1.4.1 High risk of bi Maddali 2006 Osojnik 2020 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup>	$\begin{array}{c} \text{ias studies} \\ 62.4 & 36 \\ 37 & 47 \\ \text{= } 0.00; \text{Chi}^2 = 0.19, \\ \text{t: } \text{Z} = 0.37 \text{ (P} = 0.71 \end{array}$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	6.8% 0.00 [-14.35, 14.35] 5.0% 5.00 [-12.15, 22.15] 1.8% 2.06 [-8.95, 13.06]	
1.4.2 Low risk of bia Arslan 2018 Yassen 2012 Subtotal (95% Cl) Heterogeneity: Tau <sup>2</sup> Test for overall effect	as studies 20.31 1.65 54 5.9 = 9.68; Chi <sup>2</sup> = 8.60, t: Z = 1.12 (P = 0.26	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	9.6% -4.68 [-5.16, -4.20] 8.6% 0.00 [-3.09, 3.09] 8.2% -2.60 [-7.16, 1.96]	-
<b>Total (95% CI)</b> Heterogeneity: Tau <sup>2</sup> Test for overall effect Test for subgroup dif	11 = 8.48; $Chi^2 = 10.19$ t: Z = 1.01 (P = 0.31 fferences: $Chi^2 = 0.5$	72 175 10 9, df = 3 (P = 0.02); $I^2 = 712$ 9, df = 1 (P = 0.44), $I^2 = 05$	0.0% -2.07 [-6.10, 1.96] % -	-20 -10 0 10 20 Favours NSAIDs Favours no NSAIDs
Study or Subgroup 1.6.1 High risk of bia Fayaz 2004 Khalil 2006 Subtotal (95% Cl) Heterogeneity: Tau <sup>2</sup> = Test for overall effect:	NSAID Adjuvant Mean         SD         Tota           as studies         554         401         11           733         327         21           33         327         21           34         3782.45; Chi <sup>2</sup> = 1.2         12           5         2         0.03 (P = 0.98)	No Adjuvant           I Mean         SD         Total         Weig           7         463         261         20         0.           8         30         432         19         0.           3         39         0.         7.         df = 1 (P = 0.26); l <sup>2</sup> = 21.	Mean Difference           IV, Random, 95% CI           2%         91.00 [-131.31, 313.31]           2%         -97.00 [-336.36, 142.36]           4%         2.45 [-181.48, 186.38]	Mean Difference IV, Random, 95% Cl
1.6.2 Low risk of bia Hynninen 2000 Hynninen 2000 Yassen 2012 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect:	s studies 560 260 24 630 200 24 530 230 2 268.3 0.24 25 11 e 0.00; Chi <sup>2</sup> = 2.32, d ; Z = 6.64 (P < 0.000	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	6% -20.00 [-145.82, 105.82] 8% 50.00 [-59.74, 159.74] 7% -50.00 [-168.67, 68.67] 7% -33.40 [-43.18, -23.62] 5% -32.78 [-42.46, -23.10]	•
<b>Total (95% CI)</b> Heterogeneity: Tau <sup>2</sup> = Test for overall effect: Test for subgroup diff	150 = 0.00; Chi <sup>2</sup> = 3.79, d : Z = 6.62 (P < 0.000 ferences: Chi <sup>2</sup> = 0.14	$\begin{array}{c} 160 & 100.0 \\ \text{If } = 5 \ (\text{P} = 0.58); \ \text{I}^2 = 0\% \\ 01) \\ \text{, } \text{df} = 1 \ (\text{P} = 0.71), \ \text{I}^2 = 0\% \end{array}$	0% -32.65 [-42.32, -22.99]	-500 -250 0 250 500 Favours NSAIDs Favours no NSAIDs

#### Supplemental Table 4 Grading of Recommendations Assessment, Development and Evaluation (GRADE) outcomes

№ of studies	Outcome mean measurement [95% CI]		Mean	Quality assessment					Containty		Norrativo Summeru	
(Sample Size)	NSAID adjuvant	No NSAID	[95% CI]	Risk of bias	Inconsistency	Indirectness	Imprecision	Publication bias	Other considerations	Certainty	Importance	Narrative Summary
Outcome: Reduced opiate use after 24 hours (OME, milligram)												
7 RCTs (n=418)	60.14 mg OME [56.24, 64.05]	81.52 mg OME [77.07, 85.97]	-21.38 mg OME [-30.95, -11.81] p<0.0001	None <sup>a</sup>	None <sup>b</sup>	None <sup>c</sup>	None <sup>d</sup>	Undetected <sup>e</sup>	None <sup>f</sup>	⊕⊕⊕⊕ High	IMPORTANT	NSAIDs reduce opioid use in first 24 hours.
Outcome: Red	uced pain scores aft	er 24 hours (VAS	, millimeter)									
5 RCTs (n=248)	30.23 mm [28.52, 31.94]	36.27 mm [34.67, 37.87]	-6.05 mm [-12.15, 0.06] p=0.05	None <sup>a</sup>	None <sup>b</sup>	None <sup>c</sup>	Serious <sup>g</sup>	Undetected <sup>e</sup>	None <sup>f</sup>	⊕⊕⊕⊖ Moderate	IMPORTANT	NSAIDs probably reduce pain scores at 24 hours.
Outcome: Dura	ation of mechanical	ventilation (hours	)									
8 RCTs (n=480)	6.59 hours [6.21, 6.97]	8.17 hours [7.70, 8.63]	-1.57 hours [-2.72, -0.43] p<0.007	Serious <sup>h</sup>	None <sup>b</sup>	None <sup>c</sup>	None <sup>i</sup>	Undetected <sup>e</sup>	None <sup>f</sup>	⊕⊕⊕⊖ Moderate	IMPORTANT	NSAIDs probably have no impact on duration of mechanical ventilation
Outcome: Inter	nsive care unit lengt	h of stay (hours)	,	,						•	•	
4 RCTs (n=347)	37.01 hours [34.83, 39.19]	39.08 hours [37.19, 40.97]	-2.07 hours [-6.10, 1.96] p=0.31	Serious <sup>h</sup>	Serious <sup>i</sup>	None <sup>e</sup>	None <sup>i</sup>	Undetected <sup>e</sup>	None <sup>f</sup>	⊕⊕⊖⊖ Low	IMPORTANT	NSAIDs may have no impact on ICU length of stay.
Outcomes: To	tal bleeding after 24	hours (millilitres)										
4 RCTs (n=265)	276.54 mL [270.08, 283.01]	309.23 mL [301.79, 316.66]	-32.65 mL [-42.32, -22.99] p<0.00001	Serious <sup>h</sup>	None <sup>k</sup>	None <sup>e</sup>	None <sup>i</sup>	Undetected <sup>e</sup>	None <sup>f</sup>	⊕⊕⊕⊖ Moderate	IMPORTANT	NSAIDs probably have no impact on total bleeding in first 24 hours.
Nº of studies	Anticipated abs	olute effects				Quality a	assessment					
(sample size)	Risk with NSAID Adjuvant (n, %)	Risk without NSAID (n, %)	Relative effect [95% CI]	Risk of bias	Inconsistency	Indirectness	Imprecision	Publication bias	Other considerations	Certainty	Importance	Narrative Summary
Outcome: Prev	valence of nausea or	vomiting										
8 RCTs (n=543)	52/297, 18%	64/308, 21%	0.93 [0.68, 1.28) p=0.66	Serious <sup>h</sup>	None <sup>k</sup>	None <sup>e</sup>	Very serious	Undetected <sup>e</sup>	None <sup>r</sup>	⊕⊖⊖⊖ Very low	LOW IMPORTANCE	NSAIDs have an uncertain effect on nausea/vomiting.

RCT: Randomized controlled trials, CI: Confidence interval, NSAID - Non-steroidal anti-inflammatory, OME: oral morphine equivalents, VAS: visual analogue scale

#### **GRADE Explanations**

Majority of papers had low risk of bias, subgroup analysis did not suggest effect modification based on risk of bias. Heterogeneity favors NSAID adjuvant and reflects variability in magnitude. No indirectness since all studies compared NSAID to no NSAID adjuvant analgesia. a.

b.

- c.
- 95% CI interval range does not cross no effect and meets optimal information size. d.
- No conflicts of interest in any of the papers included in the analysis. Furthermore, we reduced bias by adopting a comprehensive search strategy. e.
- No upgrades for dose dependent response or magnitude of effect. f.
- 95% CI crosses no effect g.
- Majority of papers had increased risk of bias ĥ.
- No difference within 95% CI range. i.
- High degree of heterogeneity j.
- k. 1<sup>2</sup>=0%
- 95% CI crosses no effect and insufficient optimal information size. Ι.